
About Vico
Vico is a Healthcare company based in Leiden (Netherlands) founded in 2019 by Judith Van Deutekom and Gail Mandel. RNA modulating therapies for genetic neurological diseases are developed. Vico has raised $103.3 million across 3 funding rounds from investors including EQT, Eurazeo and Idinvest Partners. Vico offers products and services including VO659 and ASO Platform. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is VICO Therapeutics B.V.
Company details
Vico was founded in 2019 in Leiden, Netherlands, within the biotechnology sector. Antisense oligonucleotide therapies are designed using the VICOMER platform to target RNA in genetic neurological disorders. Conditions addressed include Rett syndrome, Alzheimers disease, Huntingtons disease, and others. The lead program, VO659, is advanced for polyglutamine-related diseases such as spinocerebellar ataxia types 3 and 1, along with Huntingtons disease. Operations focus on therapeutic development for unmet needs in neurology.
- Headquarters Leiden, Netherlands
- Founders Judith Van Deutekom, Gail Mandel
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website vicotx.com
- Social LinkedIn X
- Legal Name Vico Therapeutics B.V.
- Total Equity Funding$103.3M (USD)
in 3 rounds
- Latest Funding Round$12.3M (USD), Series B
Jun 2024
- InvestorsEQT
& 10 more
Products & Services of Vico
Vico offers a comprehensive portfolio of products and services, including VO659 and ASO Platform.
Targets CAG repeat expansion to reduce mutant proteins in neurological diseases.
Enables precision targeting of genetic mutations for rare disorders.
Funding Insights of Vico
Vico has successfully raised a total of $103.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $12.3 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $103.3M
- Total Rounds 3
- Last Round Series B — $12.3M
- First Round $31M
(Jul 2020)
- Investors Count 11
All 3 funding rounds of Vico with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2024 | $12.3M | Series B | – | Kurma Partners, Ackermans & van Haaren | |
| Jan 2024 | $60M | Series B | – | Ackermans & van Haaren, Droia Ventures | |
| Jul 2020 | $31M | Series A | – | Life Sciences Partners, Kurma Partners |
11 investors in total: 11 institutional.
Investors in Vico
Vico has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, Eurazeo and Idinvest Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Seroba Lifesciences is focused on life sciences venture capital investments. | serobavc.com | Dublin, Ireland | ||
Biotech startups are funded through venture capital in life sciences. | 2009 | kurmapartners.com | Paris, France | |
Droia Ventures is focused on investing in drug development companies. | droiaventures.com | Luxembourg, Luxembourg | ||
EQT is recognized as a global investment organization focused on value creation. | 1994 | eqtgroup.com | Stockholm, Sweden | |
Private equity and debt investments are managed across multiple sectors. | 1969 | eurazeo.com | Paris, France | |
US focused venture capital firm | polarispartners.com | Boston, United States | ||
Venture capital is invested in innovative drug development companies. | pureosbio.com | Pfäffikon, Switzerland | ||
Private equity investments in life sciences businesses are managed. | 1998 | lspvc.com | Amsterdam, Netherlands | |
Pontifax Venture Capital is focused on life sciences investments. | pontifax.com | Herzeliya, Israel | ||
Equity investments are provided to low and middle market companies. | 1997 | idinvest.com | Paris, France |
Investor details for Vico
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Vico
31 people are tracked at Vico (10 in leadership, 8 in board & advisors, 13 in team).
| Name | Role | Group |
|---|---|---|
Judith Van Deutekom | Co-Founder & Managing Director | Leadership |
Gail Mandel | Co-Founder | Leadership |
Micah Mackison | CEO | Leadership |
Jasper Renz | Sr. Director Regulatory Affairs | Leadership |
Nicole Datson | Chief Scientific Officer & Site Head | Leadership |
Rima Shyamnani | Director Of Finance | Leadership |
Piotr Putaj | Director Oligonucleotide Chemistry | Leadership |
Scott Schobel | Chief Medical Officer | Leadership |
Paul Koevoets | Director Analytical Chemistry | Leadership |
Ruurd Verheul | Associate Director R&d | Leadership |
Felice Verduyn | Board Member | Board & advisors |
Josh Mandel-Brehm | Co-Founder & Board Member | Board & advisors |
Klaus Breiner | Board Member | Board & advisors |
Amy Schulman | Board Member | Board & advisors |
Martijn Kleijwegt | Board Member | Board & advisors |
Luc Dochez | Founder & Board Member | Board & advisors |
Remi Droller | Board Member | Board & advisors |
Anders Hinsby | Independent Board Member | Board & advisors |
Bas Rottgering | Scientist | Team |
Rani van den Eijnde | Scientist Molecular Biology | Team |
11 more people are available in the full profile.
Complete people profiles for Vico
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Vico
3 dated milestones of Vico across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Vico is founded.
- Funding First funding round of $31.0M.
- Funding Latest funding round, Series B, of $12.3M.
Web traffic of Vico
The website of Vico (vicotx.com) receives about 2.5K visits a month.
- Monthly visits2.5K
▲ 30% vs previous month
Websites whose visitors overlap most with Vico. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| interpulse.nl | 100% | #8,540,819 | View details | ||
| bataviabiosciences.com | 99% | 6.8K | #3,268,559 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vico
Complete news archive for Vico
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Vico
Vico was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Vico is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Vico is a funded company, having raised a total of $103.3M across 3 funding rounds to date. The company's 1st funding round was a Series A of $31M, raised on Jul 2020.
Vico was founded in 2019 in Leiden, Netherlands, within the biotechnology sector. Antisense oligonucleotide therapies are designed using the VICOMER platform to target RNA in genetic neurological disorders. Conditions addressed include Rett syndrome, Alzheimers disease, Huntingtons disease, and others. The lead program, VO659, is advanced for polyglutamine-related diseases such as spinocerebellar ataxia types 3 and 1, along with Huntingtons disease. Operations focus on therapeutic development for unmet needs in neurology.
Vico offers VO659 and ASO Platform.
Vico has 11 investors. Key investors include EQT, Eurazeo, Idinvest Partners, Kurma Partners, and Ackermans & van Haaren.
Vico operates through Vico Therapeutics B.V..
